Document is current

Article History

Received: 17 June 2025

Accepted: 12 October 2025

First Online: 18 November 2025

Declarations

:

: DF, in the last 2 years, had relationships as a component of the speakers’ bureau, consultant, and member of advisory boards with the following companies: Abiogen, Alfasigma, Angelini, Agave, Chiesi Daiichi-Sankyo, Grunenthal, Lundbeck, Janssen, Molteni, Sandoz, Samsung, Sobi, SPA, Viatris, and Zambon. SP declares participation as a member of the advisory board and consultancy for Sanofi, GSK, Menarini, and Zambon. FR, JPC, PSP, and GV declare no competing interests relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: This article does not express the personal opinions of the authors; rather, all the information is derived from and can be verified through the cited references. The selection of bibliographic sources was conducted in an objective and independent manner, with the aim of minimizing potential biases related to the funding source.

: Not applicable.

: All of the authors were involved in the conception and scope of the manuscript and made contribution to its development. All of the authors were involved in critically revising the manuscript for intellectual content and approved the final version. All of the authors read and approved the final version.